NASDAQ:ATXI

Avenue Therapeutics - ATXI News Today

$8.47

-6.03 (-41.59%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.12
▼
$10.50
50-Day Range: $3.21
▼
$67.50
52-Week Range: $3.00
▼
$27.75

Volume: 2.70 million shs
Average Volume: 7.04 million shs
Market Capitalization: $12.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Avenue Therapeutics News Delivered to You Automatically

ATXI Media Mentions By Week

ATXI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATXI
News Sentiment
▼
1.50

0.72
▲
Average
Medical
News Sentiment

ATXI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATXI Articles
This Week
▼
2

1
▲
ATXI Articles
Average Week

Source

Source	Headline
	Avenue Therapeutics Shares Drop 34% After Public Offering Prices marketwatch.com - October 5 at 3:47 PM
	Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer finance.yahoo.com - October 3 at 11:04 AM
	Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update americanbankingnews.com - September 28 at 1:35 AM
	Avenue Therapeutics Shareas Surge 160% marketwatch.com - September 27 at 4:38 PM
	Avenue Therapeutics Spikes 168% nasdaq.com - September 27 at 11:37 AM
	Avenue Therapeutics Shares Continue Reverse-Stock Split Slide marketwatch.com - September 26 at 2:43 PM
	Avenue Therapeutics Shares Down 38% After Reverse-Share Split marketwatch.com - September 23 at 6:15 PM
	Avenue Therapeutics Sinks 25%; Shares Start Trading After Reverse Stock Split markets.businessinsider.com - September 23 at 1:14 PM
	Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate finance.yahoo.com - September 23 at 1:14 PM
	Avenue Therapeutics Shares Rise After IV Tramadol Update, Reverse Split News marketwatch.com - September 22 at 10:26 PM
	Avenue Therapeutics up 4% on 1-for-15 reverse stock split seekingalpha.com - September 22 at 10:26 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA finance.yahoo.com - September 22 at 10:26 PM
	Take a look inside the new Avenue Pub space in downtown Tuscaloosa: ‘This is a long-term investment’ msn.com - September 7 at 7:47 AM
	Madison Avenue retail shows signs of life with six new stores nypost.com - September 5 at 3:26 PM
	1 dead, multiple others hurt after multi-vehicle crash on I-75 south at Cleveland Avenue, APD says msn.com - September 5 at 12:23 AM
	BREAKING: Police at possible barricade situation near Druid Hill Avenue in Baltimore msn.com - June 29 at 8:54 AM
	Saks Fifth Avenue closing Downtown Cincinnati location msn.com - June 22 at 5:30 PM
	SL Green Announces Sale of 609 Fifth Avenue nz.finance.yahoo.com - June 6 at 7:37 AM
	Abeona adds new CFO from Avenue Therapeutics seekingalpha.com - March 10 at 9:06 AM
	Avenue Therapeutics trebles in value on rising volume seekingalpha.com - March 1 at 5:42 PM
	The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa msn.com - February 16 at 10:56 AM
	FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol msn.com - February 16 at 10:56 AM
	Avenue Therapeutics gets FDA panel's rejection on IV pain drug seekingalpha.com - February 16 at 10:56 AM
	Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol finance.yahoo.com - February 16 at 12:31 AM
	Avenue Therapeutics Trading Halted Ahead of FDA Advisory Committee Meeting marketwatch.com - February 15 at 7:31 PM
	The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics msn.com - February 15 at 9:30 AM
	Avenue Therapeutics Stock Trading Halted Today finance.yahoo.com - February 15 at 9:30 AM
	Avenue Therapeutics IV pain therapy to go under FDA review amid safety concerns seekingalpha.com - February 11 at 6:36 PM
	Avenue Therapeutics, Inc. Common Stock (ATXI) nasdaq.com - January 23 at 8:13 PM
	Avenue Therapeutics Inc Shares Fall 2.4% Below Previous 52-Week Low - Market Mover nasdaq.com - January 11 at 3:00 AM
	Avenue Therapeutics Inc Shares Near 52-Week Low - Market Mover nasdaq.com - January 8 at 12:26 AM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Avenue Therapeutics Inc Shares Close in on 52-Week Low - Market Mover nasdaq.com - December 31 at 10:18 AM
	Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) finance.yahoo.com - December 15 at 5:32 PM
	Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock finance.yahoo.com - December 12 at 11:57 PM
	Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 finance.yahoo.com - November 29 at 10:19 AM
	Avenue Therapeutics Announces Closing of Public Offering of Common Stock finance.yahoo.com - November 12 at 11:20 AM
	Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) finance.yahoo.com - November 12 at 11:20 AM
	Avenue Therapeutics Shares Rise as FDA Panel to Meet on Appeal >ATXI marketwatch.com - October 25 at 5:10 PM
	Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs finance.yahoo.com - October 25 at 7:08 AM
	Douglas Avenue In Flossmoor Closed Early Next Week: Village msn.com - October 1 at 6:37 PM
	Avenue Capital's Marc Lasry resigns from Ozy Media chairman role msn.com - September 30 at 6:43 PM
	Parts Of Mountain Avenue Closed For Milling, Paving Project msn.com - September 30 at 1:02 PM
	3 hospitalized from multi-car crash on Colerain Avenue msn.com - September 27 at 10:31 PM
	Redevelopment plans released for Second Avenue buildings bizjournals.com - September 27 at 5:31 PM
	Man shot near Union Avenue in Providence msn.com - September 26 at 12:54 PM
	Avenue Q Walmart robbed, suspect in custody msn.com - September 25 at 3:13 PM
	Man In Mattapan Dies After Stabbing In Area Of Blue Hill Avenue And Columbia Road msn.com - August 29 at 2:15 AM
	Man In Dorchester Dies After Stabbing In Area Of Blue Hill Avenue And Columbia Road msn.com - August 29 at 2:15 AM
	Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study finance.yahoo.com - August 26 at 3:33 PM
	Gas leak prompts evacuations in San Jose near Race Street and Park Avenue msn.com - August 25 at 11:04 PM

Get Avenue Therapeutics News Delivered to You Automatically

This page (NASDAQ:ATXI) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms